TransMedics Group, Inc. (TMDX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Devices Branche. Der Hauptsitz des Unternehmens ist in Andover, MA, United States. Der aktuelle CEO ist Waleed H. Hassanein.
TMDX hat IPO-Datum 2019-05-02, 728 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $3.97B.
TransMedics Group, Inc. is a commercial-stage medical technology company headquartered in Andover, Massachusetts, focused on transforming organ transplant therapy for end-stage organ failure patients globally. The company develops and commercializes the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring platform that uses proprietary technology to maintain near-physiologic conditions for donor organs outside the human body. Its product portfolio includes OCS LUNG for lung preservation, OCS Heart for cardiac preservation, and OCS Liver for hepatic preservation, each designed to improve transplant outcomes and expand the pool of viable organs. Founded in 1998, TransMedics addresses critical challenges in organ transplantation through innovative ex vivo organ preservation technology.
